Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
AssigneesBristol-Myers Squibb Company, The Regents of the University of California
InventorsRichard S. Finn, Judy Dering, Dennis J. Slamon, Charles L. Ginther, Edwin A. Clark
Life of this patent
Estimating the term…
Abstract
The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
Claims15
A method for determining the responsiveness of a mammalian breast tumor cell to treatment with N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide or a pharmaceutically acceptable salt, solvate, or hydrate thereof, the method comprising determining the level of expression of yes-associated protein 1 in a biological sample comprising a breast tumor cell;
- and correlating a finding of elevated expression of yes-associated protein 1, as compared to the level of expression of a control, with said breast tumor cell being sensitive to said treatment with N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
A method for determining the responsiveness of an individual with breast cancer to treatment with N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising:
- obtaining a biological sample comprising a breast tumor cell from said individual;
- and
- determining the level of expression in said biological sample comprising a breast tumor cell of yes-associated protein 1;
- and
- correlating a finding of elevated expression of yes-associated protein 1, as compared to the level of expression of a control, with said breast tumor cell being sensitive to said treatment with N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
Dependencies are inferred from the claim text.